drugset / Trial / NCT01981837
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-10
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALN-TTRSC | Unknown | — | Subcutaneous |
Indications
No indication recorded.